Frequency of hCD45+ (Percent of Viable Cells) 5. 10. 15. 0. 20. Days post-TIL transfer. D14. No EP KSQ-004EX No EP KSQ-004EX * NSCLC. PDAC. D21. D28. D56. 10. 20. 40 ...

Tackling the toughest challenges in medicine with the aspiration to cure human diseases.

0 10 20 30 40 50 % OT1s of CD8s 0 20 40 60 80 100 % of OT1 ns TH. D. ual inactivationof SOCS1 and Regnase-1 in T Cell Therapies Demonstrated Enhanced

A Phase 1/2 Study of KSQ-001EX: An autologous Tumor Infiltrating Lymphocyte Therapy engineered to inactivate the SOCS1 gene, in Patients with Select Advanced Solid Tumors Rodabe N. Amaria 1, Michael A. Davies 1, Alexandra Ikeguchi 1, Jennifer L. McQuade 1, Adi Diab 1, Hussein A. Tawbi 1, Isabella C. Glitza Oliva 1, Youlia Petrova 1, …

2021年1月13日 · Collaboration includes two T-cell programs and an expansive discovery program to identify natural killer (NK) cell targets Potential for more than $100M in upfront and preclinical milestone payments, and eligible to receive additional development and commercialization milestone payments for each product KSQ retains a U.S. cost/profit-sharing option on one product, and is entitled to potential

KSQ-001EX is an investigational eTIL therapy manufactured using our ExPRESS™ process in which the SOCS1 gene is inactivated by CRISPR/Cas9 gene editing.; KSQ’s Immune CRISPRomics ® platform identified SOCS1 as a top target, constraining TIL anti-tumor function, engraftment, and persistence.; The U.S. Food and Drug Administration (FDA) has cleared an Investigational New Drug (IND ...

KSQ-001: A CRISPR/Cas9-Engineered Tumor Infiltrating Lymphocyte ( eTILTM) Therapy for Solid Tumors. Adoptive cell therapy (ACT) with ex vivo expanded tumor infiltrating lymphocytes (TIL)

Lexington, Mass., October 22, 2024 — KSQ Therapeutics, Inc. (KSQ), a clinical-stage biotechnology company developing novel treatments for solid tumors, today announced the appointment of John Lepore, M.D., to the company’s board of directors. Dr. Lepore brings over 20 years of leadership experience in R&D and drug discovery to KSQ’s board. “As …

2024年9月24日 · Phase 1/2 clinical study will evaluate the safety and preliminary efficacy of KSQ-004EX in advanced solid tumors Lexington, Mass., September 24, 2024 — KSQ Therapeutics, Inc. (KSQ), a clinical-stage biotechnology company developing novel treatments for solid tumors, in collaboration with The University of Texas MD Anderson Cancer Center (MD Anderson) and the Cell Therapy Manufacturing

2024年10月8日 · Anna Truppel-Hartmann is a seasoned medical professional with over 15 years of experience in the pharmaceutical and biotechnology sectors. She earned her medical degree in Switzerland and brings a wealth of expertise and accomplished track record in clinical development, medical affairs, patient engagement, and talent development. She has held key leadership roles at both large